PF 4382923

Drug Profile

PF 4382923

Alternative Names: PF-04382923; PF4382923; RN-6G

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antibodies; Eye disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dry age-related macular degeneration

Most Recent Events

  • 09 May 2013 Discontinued - Phase-II for Dry age-related macular degeneration in United Kingdom (IV)
  • 09 May 2013 Discontinued - Phase-II for Dry age-related macular degeneration in USA (IV)
  • 27 Mar 2013 Pfizer completes a phase I trial in Dry age-related macular degeneration in USA (NCT01003691)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top